Supriya Lifescience Shares Lists At 55% Premium Over Issue Price
Supriya Lifescience’s IPO was subscribed 71.47 times till the end of its bidding process.
Shares of Supriya Lifescience made a strong start on Tuesday, December 28 amid positive market sentiment. Shares of the active pharmaceutical ingredients (API) maker opened at Rs 425 on the BSE – a premium of 55.1 per cent or Rs 151 more than the issue price of Rs 274. On NSE, the shares of Supriya Lifesciences were listed at Rs 421. – Premium of 53.7 percent.
With its launch, Supriya Lifesciences has emerged as one of the strongest listings in recent times. The IPO of Supriya Lifesciences was open for subscription from December 16 to December 20. The initial public offer (IPO) of Rs 700 crore was subscribed 71.47 times till the end of its bidding process. The IPO had a fresh issue of up to Rs 200 crore and an offer for sale of up to Rs 500 crore. The company sold shares in the price band of Rs 265-274 per equity share. The company raised Rs 315 crore from anchor investors ahead of its IPO.
BNP Paribas Arbitrage, Societe Generale, Reliance General Insurance Company, Aditya Birla Sun Life Insurance Company, Kuber India Fund, Cent Capital Fund and Nippon India Mutual Fund were among the anchor investors. ICICI Securities and Axis Capital were the book running lead managers of the public issue.
Supriya Lifescience is one of the leading Indian manufacturers and suppliers of Active Pharmaceutical Ingredients (APIs), focusing on R&D. As of March 2021, the company produces 38 APIs focused on diverse therapeutic segments such as Antihistamine, Analgesic, Anesthetic, Vitamin, Anti-Asthma and Anti-Allergy. The company is one of the largest exporters of Salbutamol Sulphate from India in terms of volume in the FY 2020-21.
